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Abstract
The influence of enrofloxacin administration (5 mg/kg) for five consecutive days on the occurrence
of Pasteurella multocida in the upper respiratory tract of two healthy calves was monitored over a
10-day period. From nasal swabs of two additional healthy control calves, which received a placebo
saline administration, P. multocida was isolated throughout the study period. In the enrofloxacin
treated calves, P. multocida was not demonstrated in the nasopharynx from 48 h after the first
injection until two days after the last administration, when P. multocida reappeared and proved to
be clonal in nature to the original isolates. During the experiment, no change in minimal inhibitory
concentration for enrofloxacin of the P. multocida isolates was detected (MIC ≤ 0.015 μg/mL).
Enrofloxacin concentrations were determined in the plasma by a high-performance liquid
chromatography method with fluorescence detection. The PK/PD indices AUC/MIC and Cmax/MIC
ratio were calculated and found to be 1157.7 and 129.8, respectively. Remarkably, the respiratory
pathogen Arcanobacterium pyogenes became the predominant recovered organism in the
nasopharynx of one animal following enrofloxacin therapy throughout the remaining of the
experiment.
Findings
In calves, enrofloxacin is frequently used to treat pneu-
monic pasteurellosis, a disease mostly due to Pasteurella
multocida [1]. P. multocida is a common inhabitant of the
upper respiratory tract of calves. To better understand the
epidemiology of pneumonic pasteurellosis and the occur-
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how systemic fluoroquinolone administration affects the
flora of the nasopharynx in healthy calves. This is impor-
tant as metaphylaxis is a common practice in the preven-
tion of bovine respiratory diseases. Preventive treatment
of "at risk animals" may be associated with a selection
pressure leading to antimicrobial resistance or a shift in
the population of bacteria present in the nasopharynx.
The aim of the present experiment was to evaluate the
influence of consecutive systemic enrofloxacin adminis-
trations on the presence and susceptibilities of P. multoc-
ida strains naturally present in the nasopharynx of
clinically healthy calves and to find a relationship with
pharmacokinetic/pharmacodynamic surrogate parame-
ters.
Four dairy calves aged 24–28 days were loose group-
housed together during a 5-day pre-experimental period
after which the calves were randomly assigned to either a
treatment group or a control group. Inclusion criteria were
the absence of disease and antimicrobial therapy since
birth. The calves were housed two by two in straw-bedded
pens (approximately 18 m2 of floor space per group) in
the same automated ventilated stable (17 ± 2°C), but
divided by full wooden partitions approximately 1.4 m
high. Management and hygienic measures were set up to
prevent direct contact between the two study groups.
Water and hay were supplied ad libitum, and the calves
were maintained on an antibiotic-free milk replacer diet
twice a day. Clinical observations were carried out and all
calves remained healthy during the entire experiment.
The study lasted for 10 days (D0–D9). For five consecutive
days (D0–D4), the two calves of the treatment group
(weights at D0: 47.0 and 49.2 kg) were injected intramus-
cularly with 5 mg/kg enrofloxacin (Baytril 2.5%, Bayer,
Milan, Italy), while the two calves of the control group
(weights at D0: 48.7 and 50.0 kg) received a placebo (5
mL isotonic saline intramuscularly). After disinfection of
the nostrils with 90% ethanol, nasal samples were col-
lected using cotton swabs inserted 10–15 cm into the dor-
sal conchae (Venturi Transsystem, Copan, Italy) every 12
h starting from D0 until D5 and on D6 and D9. Samples
were cooled (< 7°C) and further processed within 24 h,
starting by vortexing each swab in 3 mL phosphate buff-
ered saline for 10 s. Plasma samples obtained by centrifu-
gation of blood at 4 × g for 10 min were taken on D0 at 0,
2, 4, 6, 12, 24 h, on D1 at 48 h, on D2 at 72 h, on D3 at
96 h, and on D4 at 100, 104, 108, 112, 120, 144 and 216
h (the latter intensity to explore the elimination phase)
from the treated calves and from the placebo calves at 0 h
(D0), and stored at -20°C prior to assay. The experimental
protocol was approved by the local ethics committee.
In the nasal samples, the numbers of enrofloxacin resist-
ant P. multocida isolates and the total numbers of P. mul-
tocida isolates were determined using a comparative
enumerating procedure (duplicate aliquots of 25 μL) on
Columbia agar (Oxoid, Hampshire, UK) to which sheep
blood (5% vol/vol) and 16 μg/mL bacitracin (1 μg equals
0.0654 U, Sigma Poole, UK) was added with the following
concentrations of enrofloxacin (Baytril 2.5%): 0; 0.06;
0.125; 0.25; 0.5, and 1 μg/mL. Reading was performed
after 24 h and 48 h of aerobic incubation at 37°C, and
consisted of counting colony-forming units (CFU) distrib-
uted over each drop zone and averaged for duplicates. The
species identification of one P. multocida colony per ani-
mal per day was confirmed by means of phenotyping and
tDNA-PCR and clonality was examined by means of
pulsed-field gel electrophoresis (PFGE) [1]. Bacteriologi-
cal counts were expressed as median and interquartile
range, and a non-parametric multivariate analysis of vari-
ance (nonparametric MANOVA) for repeated measure-
ments and small sample sizes [2] was performed (SAS
version 9.1, Sat Institute Inc., Cary, NC). Evolution of P.
multocida recovery from the nasal swabs on media without
enrofloxacin in both the treated calves and the control
calves is given in Figure 1. The non-parametric MANOVA
showed that the difference in P. multocida isolation was
significant between the treatment and the placebo group
over time (treatment*time P = 0.04, time P = 0.03). P.
multocida was not recovered during the entire experiment
on media containing any of the enrofloxacin concentra-
tions. Additional susceptibility testing [1] (range 0.015–1
μg/mL) confirmed no detectable increase in enrofloxacin
MIC (≤ 0.015 μg/mL) of seven P. multocida isolates recov-
ered from both treated calves on D0 (2) and on D9 (2)
and from the control calves on D0 (1) and D9 (2), and
PFGE fingerprinting patterns were identical. Whether the
clonally identical organisms reappeared in the treated
calves either through airborne transmission from the con-
trol calves or endogenously via undetected strains, e.g. in
the tonsils, is unclear.
To evaluate whether the microbiological effects of fluoro-
quinolone administration were in line with the current
understanding of pharmacokinetic/pharmacodynamic
(PK/PD) relationships, two PK/PD parameters were calcu-
lated: the maximum plasma concentration/minimal
inhibitory concentration (Cmax/MIC) ratio and the area
under the inhibitory curve (AUC/MIC). Theoretically,
Cmax/MIC should exceed 10 and AUC/MIC (AUIC)
should exceed 125 to minimize the selection for resistant
organisms by bacterial killing also of less susceptible sub-
populations (eradication) [3,4].
Plasma concentrations of enrofloxacin and its active
metabolite ciprofloxacin were determined using a vali-
dated high-performance liquid chromatography methodPage 2 of 4
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formed as described by Manceau et al. [5], with minor
modifications. Pharmacokinetic analysis was performed
using MW/Pharm software (version 3.60, Medi Ware,
Utrecht, The Netherlands). The plasma concentration-
time profile could be adequately fitted to a one compart-
mental model (r2 ≥ 0.996 for enrofloxacin and r2 ≥ 0.973
for ciprofloxacin). All concentrations in the placebo calves
were below the limit of detection (4.6 ng/mL). Maximal
plasma concentration (Cmax), elimination rate constant
(ke) and elimination half-life (T1/2e) were derived from
the model. The area under the curve from time zero to
infinity after the first dose (AUC0→∞) was calculated using
the linear trapezoidal method for AUC0→t and adding the
estimated terminal portion of the curve (Ct/ke), where t is
the last time of measurable plasma concentrations after
the first dose. Enrofloxacin is de-ethylated into cipro-
floxacin, but the degree of this metabolic process substan-
tially varies within animal species. The mean ratio in
AUC0→∞ of ciprofloxacin/enrofloxacin after the first dose
found here was 12.3%. This was significantly lower than
reported in 8-month-old buffalo calves (27%) and adult
cattle (29.9%) [6]. In newborn and one-week-old calves
the ciprofloxacin/enrofloxacin ratio can range from 10 to
27%. The ratio is probably lower in young calves due to
the lower metabolic capacity at this age [7]. The area
under the concentration-time curve at steady-state over 24
h (AUC0→24 h) was set equivalent to the AUC0→∞ after the
first dose. The ratio of AUC0→24 h/MIC (AUIC) and plasma
Cmax/MIC was expressed as a dimensionless value. For the
isolated P. multocida strains the mean AUIC and Cmax/MIC
for enrofloxacin were found to be 1157.7 and 129.8,
respectively (MIC for enrofloxacin ≤ 0.015 μg/mL). Even
when a conservative MIC of 0.06 μg/mL [1] is taken into
account, the thresholds would successfully be exceeded
(289.4 for AUIC; 32.4 for Cmax/MIC). Unfortunately, the
obtained values rely on the plasma concentrations and
not on concentrations measured in the nasopharynx. Nev-
ertheless, several studies dealing with pharmacokinetics
of fluoroquinolones in both plasma and at the site of
infection are available in cattle and in line with our obser-
vations [8,9]. Recently, it has been shown that fluoroqui-
nolones are a substrate for ATP-dependent efflux
transporters which may result in effective drug concentra-
tions in luminal compartments of target tissues [10,11] In
addition, during natural courses of bovine respiratory dis-
ease, the PK/PD surrogate markers for fluoroquinolones
can largely exceed those seen in apparently healthy ani-
mals [12].
In one calf of the enrofloxacin treated group, a quasi pure
culture of Arcanobacterium pyogenes was recovered from D2
Recovery of Pasteurella multocida (colony forming units, CFU) in the nasopharynx of calves treated with enrofloxacin and con-trol calves on media without enrofl xacinFigur  1
Recovery of Pasteurella multocida (colony forming units, CFU) in the nasopharynx of calves treated with enro-
floxacin and control calves on media without enrofloxacin. Error bars indicate median and interquartile range.Page 3 of 4
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(2.9 log10 CFU/mL) onwards and increased in numbers
(up to 4.5 log10 CFU/mL at D4) to remain persistent dur-
ing the remaining time of the experiment. A. pyogenes was
identified as previously described[13] and the occurrence
was observed on the selective media containing ≤ 0.25 μg/
mL enrofloxacin. The latter is in agreement with the study
of Yoshimura et al. [14] who found a MIC of 0.5 μg/mL
for A. pyogenes and in accordance with a report by Naray-
anan et al. [15], that support our finding that bovine A.
pyogenes strains are able to grow on the selective media
containing 16 μg/mL bacitracin (equals approximately 1
U/mL). A. pyogenes is an opportunistic bovine pathogen
associated with chronic manifestations of bovine respira-
tory disease.
In conclusion, a temporary eradication effect of enro-
floxacin for P. multocida in the nasopharynx of treated
calves was present. This is in line with the current PK/PD
approach to prevent the selection of resistance, since the
AUIC and the Cmax/MIC ratio measured in the present
study largely exceeded the generally accepted thresholds
of 125 and 10, respectively. Although confirmation is
needed, our results suggest that other respiratory patho-
gens like A. pyogenes, which are intrinsically less suscepti-
ble for enrofloxacin, are able to colonise the upper
respiratory tract during fluoroquinolone therapy.
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